[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDAC34RAcXPkNMq7RObANilQwTmMSrhTp-pJjXn0w0TM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":20,"phaseBuckets":26,"rows":33},"Osivax",[4],10,false,1,0,4469,2,[13,16,18],{"name":14,"count":15},"Influenza",9,{"name":17,"count":8},"Coronavirus",{"name":19,"count":8},"Vaccine-Preventable Diseases",[21],{"nctId":22,"briefTitle":23,"date":24,"intervention":25},"NCT05569239","Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg","2026-05-29","OVX836 480µg",[27,28,29,30,31,32],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[34,81,122,156,174,192,216,234,252,270],{"intervention":35,"totalTrials":36,"cells":37},"Saline solution",3,{"EARLY_PHASE1":38,"PHASE1":40,"PHASE2":54,"PHASE3":75,"PHASE4":77,"NA":79},{"trials":39,"activeCount":9},[],{"trials":41,"activeCount":9},[42],{"nctId":43,"briefTitle":44,"status":45,"phases":46,"primaryCompletion":47,"completion":48,"start":49,"enrollment":50,"conditions":51,"interventions":52},"NCT06128382","First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers","COMPLETED",[28],"2024-07-08","2024-11-29","2024-01-08",48,[17],[53,35],"OVX033",{"trials":55,"activeCount":8,"soonestReadout":24},[56,67],{"nctId":57,"briefTitle":58,"status":45,"phases":59,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":65},"NCT05060887","Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.",[29],"2022-02-01","2022-12-07","2021-11-15",239,[14],[66,35],"OVX836-003",{"nctId":22,"briefTitle":23,"status":68,"phases":69,"primaryCompletion":24,"completion":24,"start":70,"enrollment":71,"conditions":72,"interventions":73},"ACTIVE_NOT_RECRUITING",[29],"2025-09-08",2850,[14],[25,74],"Saline Solution",{"trials":76,"activeCount":9},[],{"trials":78,"activeCount":9},[],{"trials":80,"activeCount":9},[],{"intervention":25,"totalTrials":36,"cells":82},{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":87,"PHASE3":116,"PHASE4":118,"NA":120},{"trials":84,"activeCount":9},[],{"trials":86,"activeCount":9},[],{"trials":88,"activeCount":8,"soonestReadout":24},[89,101,105],{"nctId":90,"briefTitle":91,"status":45,"phases":92,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT05734040","Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.",[29],"2023-08-10","2024-01-15","2023-05-10",478,[14],[25,99,100],"Fluarix Tetra","Afluria Quad",{"nctId":22,"briefTitle":23,"status":68,"phases":102,"primaryCompletion":24,"completion":24,"start":70,"enrollment":71,"conditions":103,"interventions":104},[29],[14],[25,74],{"nctId":106,"briefTitle":107,"status":45,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT05284799","Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.",[29],"2022-07-19","2022-12-09","2022-05-09",180,[14],[25,115],"Quadrivalent Inactivated Influenza Vaccine",{"trials":117,"activeCount":9},[],{"trials":119,"activeCount":9},[],{"trials":121,"activeCount":9},[],{"intervention":123,"totalTrials":11,"cells":124},"OVX836",{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":138,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":126,"activeCount":9},[],{"trials":128,"activeCount":9},[129],{"nctId":130,"briefTitle":131,"status":45,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT03594890","Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects",[28],"2019-08-07","2018-06-12",72,[14],[123,123],{"trials":139,"activeCount":9},[140],{"nctId":141,"briefTitle":142,"status":45,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":148},"NCT04192500","Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years",[29],"2020-09-07","2019-12-11",300,[14],[123,149],"Quadrivalent seasonal influenza vaccine",{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[],{"intervention":149,"totalTrials":8,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":159,"activeCount":9},[],{"trials":161,"activeCount":9},[],{"trials":163,"activeCount":9},[164],{"nctId":141,"briefTitle":142,"status":45,"phases":165,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":166,"interventions":167},[29],[14],[123,149],{"trials":169,"activeCount":9},[],{"trials":171,"activeCount":9},[],{"trials":173,"activeCount":9},[],{"intervention":66,"totalTrials":8,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":186,"PHASE4":188,"NA":190},{"trials":177,"activeCount":9},[],{"trials":179,"activeCount":9},[],{"trials":181,"activeCount":9},[182],{"nctId":57,"briefTitle":58,"status":45,"phases":183,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":184,"interventions":185},[29],[14],[66,35],{"trials":187,"activeCount":9},[],{"trials":189,"activeCount":9},[],{"trials":191,"activeCount":9},[],{"intervention":193,"totalTrials":8,"cells":194},"OVX836 shot",{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":196,"activeCount":9},[],{"trials":198,"activeCount":9},[],{"trials":200,"activeCount":9},[201],{"nctId":202,"briefTitle":203,"status":45,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"NCT06582277","Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836",[29],"2025-06-02","2024-10-22",117,[19,14],[193],{"trials":211,"activeCount":9},[],{"trials":213,"activeCount":9},[],{"trials":215,"activeCount":9},[],{"intervention":99,"totalTrials":8,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":219,"activeCount":9},[],{"trials":221,"activeCount":9},[],{"trials":223,"activeCount":9},[224],{"nctId":90,"briefTitle":91,"status":45,"phases":225,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":226,"interventions":227},[29],[14],[25,99,100],{"trials":229,"activeCount":9},[],{"trials":231,"activeCount":9},[],{"trials":233,"activeCount":9},[],{"intervention":100,"totalTrials":8,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":237,"activeCount":9},[],{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":9},[242],{"nctId":90,"briefTitle":91,"status":45,"phases":243,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":244,"interventions":245},[29],[14],[25,99,100],{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[],{"trials":251,"activeCount":9},[],{"intervention":115,"totalTrials":8,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[],{"trials":259,"activeCount":9},[260],{"nctId":106,"briefTitle":107,"status":45,"phases":261,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":262,"interventions":263},[29],[14],[25,115],{"trials":265,"activeCount":9},[],{"trials":267,"activeCount":9},[],{"trials":269,"activeCount":9},[],{"intervention":53,"totalTrials":8,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":286},{"trials":273,"activeCount":9},[],{"trials":275,"activeCount":9},[276],{"nctId":43,"briefTitle":44,"status":45,"phases":277,"primaryCompletion":47,"completion":48,"start":49,"enrollment":50,"conditions":278,"interventions":279},[28],[17],[53,35],{"trials":281,"activeCount":9},[],{"trials":283,"activeCount":9},[],{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[]]